24/04/2024
To the Shareholders of Immunotech Laboratories Inc (IMMB) and the Partners of Immunotech Laboratories BG
Dear shareholders,
The medicinal products on the basis of the IPF platform – ITV-1, ITV-2, ITV-3, ITV-4, ITV-5 with US Patents № 7,479,538, № 7,625,565, № 8,066,982, № 8,067,531, № 8,309,072 and the exclusive rights over the production and distribution with a notary signed in the US agreement are the property of Immunotech Laboratories BG until 2030. Every reference to these patents and the clinical trial of ITV-1 by Enzolytics Inc, as well as other entities, is a breach of the exclusive rights of Immunotech Laboratories BG, which is illegal and punishable by law. We have informed the former and current management of Enzolytics, namely Charles Cotropia, Harry Zhabilov, Luchezar Ivanov that any reference to these patents on their side is illegal and made with the goal of misleading shareholders and investors, regarding which we will inform the competent court and the public. In his attempt to bankrupt Immunotech Laboratories, Inc. (IMMB), Harry Zhabilov who was formerly the CEO, resigned from all positions on November, 2019 without informing the shareholders. In this way, he left the company without management, which he hid from all shareholders. Zhabilov also misappropriated the $190,000 wired by our company to IMMB for the validation batches, thus causing delay of the ITV-1 project. Zhabilov committed these actions in an attempt to illegally transfer all assets from Immunotech Laboratories Inc. to Enzolytics Inc., which has caused damages and lost profits to the shareholders of Immunotech Laboratories Inc. We will soon conduct a validation of the medicinal product ITV-1 with US Patent № 7,479,538 and the estimated release on the market is until 01/31/2022. In order to organize the production and bring ITV-1 to the market, Immunotech Laboratories BG signed a Joint Business Agreement with a strategic partner Nika Pharmaceuticals, Inc. (OTCMKTS: NKPH) through which the two companies are combining their efforts to realize the registration, production and distribution of medicinal products based on the Inactivated Pepsin Fraction (“IPF”) platform with U.S. Patents Nº 7,479,538, 7,625,565, 8,066,982, 8,067,531, 8,309,072.
For additional information you can contact us on the electronic mail immunotechlabsbg@gmail.com or visit the website www.immunh.com
Dimitar Savov
General Manager
Immunotech Laboratories BG
